Research published online yesterday in the journal Health Affairs suggests that 340B hospitals are less likely than others to use biosimilar drugs, “possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.”
Groups that represent 340B hospitals are expected to issue rebuttals. Drug manufacturers and others likely will cite it as more evidence why 340B must change.
Research published online yesterday in the journal Health Affairs suggests that 340B hospitals are less likely than others to use biosimilar drugs, “possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.” Groups that represent […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
